CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis

Gut

Volumn 63, Issue 12, 2014, Pages 1960-1971

  Ehling, Josef ^a   Bartneck, Matthias ^a   Wei, Xiao ^a   Gremse, Felix ^a   Fech, Viktor ^a   Möckel, Diana ^a   Baeck, Christer ^a   Hittatiya, Kanishka ^b   Eulberg, Dirk ^c   Luedde, Tom ^a   Kiessling, Fabian ^a   Trautwein, Christian ^a   Lammers, Twan ^a,d,e   Tacke, Frank ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c NOXXON PHARMA AG   (Germany)

^d UNIVERSITY OF TWENTE   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CARBON TETRACHLORIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NOX-E36-3'PEG, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MACROPHAGE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; APTAMERS, NUCLEOTIDE; CARBON TETRACHLORIDE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; X-RAY MICROTOMOGRAPHY;

EID: 84894072682     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306294     Document Type: Article

References (31)

1. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002;35:1010-21.
2. Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185-95.
3. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infi ltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-26.
4. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901.
5. Hong F, Chou H, Fiel MI, et al. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 2013;58:257-64.
6. Coulon S, Heindryckx F, Geerts A, et al. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-62.
7. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010;30:258-70.
8. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013;2013:187204.
9. Matsubara T, Kanto T, Kuroda S, et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology 2013;57:1416-25.
10. Coulon S, Legry V, Heindryckx F, et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 2013;57:1793-805.
11. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer cell 2013;23:277-86.
12. Baeck C, Wehr A, Karlmark KR, et al . Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012;61:416-26.
13. Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009;50:261-74.
14. Ramachandran P, Pellicoro A, Vernon MA, et al . Differential Ly-6C expression identi fies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012;109:E3186-95.
15. Tacke F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair 2012; 5(Suppl 1):S27.
16. Ehling J, Lammers T, Kiessling F. Non-invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost 2013;109:375-90.
17. Karlmark KR, Zimmermann HW, Roderburg C, et al. The fractalkine receptor CX(3) CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010;52:1769-82.
18. Hammerich L, Bangen JM, Govaere O, et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 2014;59:630-42.
19. Gremse F, Grouls C, Palmowski M, et al. Virtual elastic sphere processing enables reproducible quantification of vessel stenosis at CT and MR angiography. Radiology 2011;260:709-17.
20. Ehling J, Theek B, Gremse F, et al. Micro-CT Imaging of Tumor Angiogenesis: Quantitative Measures Describing Micromorphology and Vascularization. Am J Pathol 2014;184:431-41.
21. Zhang J, Tao R, You Z, et al. Gamna-Gandy bodies of the spleen detected with susceptibility weighted imaging: maybe a new potential non-invasive marker of esophageal varices. PloS one 2013;8:e55626.
22. Lessa AS, Paredes BD, Dias JV, et al. Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats. BMC Vet Res 2010;6:6.
23. O'Donohue J, Ng C, Catnach S, et al. Diagnostic value of Doppler assessment of the hepatic and portal vessels and ultrasound of the spleen in liver disease. Eur J Gastroenterol Hepatol 2004;16:147-55.
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
25. Avraham-Davidi I, Yona S, Grunewald M, et al. On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. J Exp Med 2013;210:2611-25.
26. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related infl ammation. J Leukoc Biol 2009;86:1065-73.
27. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
28. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302. e4.
29. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008;135:32-40.
30. Ehling J, Bartneck M, Fech V, et al. Elastin-based molecular MRI of liver fibrosis. Hepatology 2013;58:1517-18.
31. Polasek M, Fuchs BC, Uppal R, et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012;57:549-55.